Phase II Trial of Dual LAG-3–PD-1 Inhibition With Neoadjuvant Relatlimab + Nivolumab in Resectable Stage III Melanoma

Neoadjuvant relatlimab plus nivolumab produced high rates of pCR and MPR in patients with resectable stage III melanoma with a tolerable safety profile.